Cartesian Therapeutics Reports Board & Executive Changes
Ticker: RNAC · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $385,000, $80,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Board shakeup and exec comp changes at Cartesian Therapeutics.
AI Summary
On October 2, 2025, Cartesian Therapeutics, Inc. reported changes in its board of directors and executive compensation arrangements. The filing indicates the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty and signal potential strategic shifts, which may carry moderate risk.
Key Numbers
- 001-37798 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-1622110 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- October 2, 2025 (date) — Date of earliest event reported
- October 8, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Frederick, MD (location) — Principal executive offices
FAQ
What specific roles have been affected by the departure of directors or officers?
The filing indicates the departure of directors or certain officers, and the election of new directors, but does not specify the exact roles vacated or filled in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 2, 2025.
What is the principal executive office address for Cartesian Therapeutics, Inc.?
The principal executive offices are located at 7495 New Horizon Way, Frederick, MD 21703.
What is the SEC file number for Cartesian Therapeutics, Inc.?
The SEC file number for Cartesian Therapeutics, Inc. is 001-37798.
What type of compensatory arrangements are mentioned in the filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, indicating changes or updates to executive compensation.
Filing Stats: 1,103 words · 4 min read · ~4 pages · Grade level 11.8 · Accepted 2025-10-08 07:00:02
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
- $385,000 — led to receive an annual base salary of $385,000 and Ms. Seymour will be eligible for an
- $80,000 — eceive a sign-on bonus in the amount of $80,000 and was granted an option to purchase 5
Filing Documents
- rnac-20251002.htm (8-K) — 31KB
- 0001453687-25-000104.txt ( ) — 146KB
- rnac-20251002.xsd (EX-101.SCH) — 2KB
- rnac-20251002_lab.xml (EX-101.LAB) — 21KB
- rnac-20251002_pre.xml (EX-101.PRE) — 12KB
- rnac-20251002_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: October 8, 2025 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer